Oppenheimer analyst Suraj Kalia maintained a Buy rating on Resmed (NYSE:RMD) Inc on Thursday, setting a price target of $212, which is approximately 17.35% above the present share price of $180.66.
Kalia expects Resmed Inc to post earnings per share (EPS) of $1.23 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Resmed, with an average price target of $180.
The analysts price targets range from a high of $212 to a low of $145.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $770.34 million and a net profit of $223.25 million. The company's market cap is $26.52 billion.
According to TipRanks.com, Oppenheimer analyst Suraj Kalia is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 3.5% and a 51.29% success rate.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.